| Name | Title | Contact Details |
|---|
Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.
Meda is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ADARx is a genetic medicine company focusing on the editing of Messenger RNA Targeting transcripts and oligonucleotide-based therapeutics.
Concept Matrix Solutions is a company that specializes in the formulation, development, and manufacturing of novel drug delivery systems utilizing CBD from Industrial Hemp and other cannabinoids, as well as Nutraceuticals. They also provide the highest...
With locations in South Jordan & Riverton Utah, our experienced pediatricians & caring team of professionals provides comprehensive care for your children.